

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/007015

International filing date: 03 March 2005 (03.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/552,501
Filing date: 11 March 2004 (11.03.2004)

Date of receipt at the International Bureau: 07 April 2005 (07.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1301774

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 31, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/552,501

FILING DATE: *March 11, 2004*

RELATED PCT APPLICATION NUMBER: *PCT/US05/07015*



Certified by

Don W. Dudas

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

031104
17364 U.S. PTO

17685 PROV (AP)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Provisional Application of
Shen

For: METHODS AND COMPOSITIONS FOR THE
TREATMENT OF CONDITIONS RELATED TO
GASTRIC ACID SECRETION

19587 U.S. PTO
60/552501

031104

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

Mail Stop: Provisional Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT
under 37 CFR 1.53(c).

1. The enclosed PROVISIONAL APPLICATION includes the following:
 - a. Specification (34 pgs);
 - b. Claims 20 (2 pgs);
 - c. Abstract (1 pg);
 - d. Drawings (3 sheets).
 - e. Assignment w/Cover Sheet (4 pgs.)
2. Inventors:

Given Name	Residence
1. Jie Shen	137 Giotto Irvine, CA 92614
2. Devin F. Welty	37 Tessera Avenue Foothill Ranch, CA 92610
3. Diane D. Tang-Liu	2615 Blackthorn Street Newport Beach, CA 92660

3. Fee Payment

Please charge to Deposit Account No. 01-0885 for the filing fee of \$160.00, as well as for any discrepancies that may occur.

4. Postcard Receipt

Applicant submits herewith a Return/Stamped Postcard.

Respectfully submitted,

Date: March 11, 2004

By: Brent A. Johnson
Brent A. Johnson, Ph.D.
Patent Agent
Registration No. 51,851
Tel: 714/246-4348
Fax: 714/246-4249

Please address all future correspondence to:

Brent A. Johnson, Ph.D.
ALLERGAN, INC.
2525 Dupont Drive, T2-7H
Irvine, CA 92612
Tel: 714/246-4348
Fax: 714/246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. §1.10

I hereby certify that this Provisional Patent Application and the documents referred to as enclosed herein are being deposited with the United States Postal Service on March 11, 2004 in an envelope as "Express Mail Post Office To Addressee" mailing label number EV193720901US with sufficient postage for Express Mail addressed to Mail Stop Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: March 11, 2004

Susan Bartholomew
Name of person mailing paper
Susan Bartholomew
Signature of person mailing paper

**METHODS AND COMPOSITIONS FOR THE TREATMENT OF
CONDITIONS RELATED TO GASTRIC ACID SECRETION**

By Inventors

Jie Shen, Devin F. Welty and Diane D. Tang-Liu

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to pharmaceutical compositions and methods. In particular, this inventions relates to pharmaceutical compositions and methods related to diseases and conditions of the gastrointestinal tract.

Description of the Related Art

Benzimidazole derivatives intended for inhibiting gastric acid secretion are disclosed in U.S. Pat. Nos. 4,045,563; 4,255,431; 4,628,098; 4,686,230; 4,758,579; 4,965,269; 5,021,433; 5,430,042 and 5,708,017. Generally speaking, the benzimidazole-type inhibitors of gastric acid secretion are believed to work by undergoing a rearrangement to form a thiophilic species which then covalently binds to gastric H,K-ATPase, the enzyme involved in the final step of proton production in the parietal cells, and thereby inhibits the enzyme. Compounds which inhibit the gastric H,K-ATPase enzyme are generally known in the field as "proton pump inhibitors" (PPI).

Some of the benzimidazole compounds capable of inhibiting the gastric H,K-ATPase enzyme have found substantial use as drugs in human medicine and are known under such names as LANSOPRAZOLE (U.S. Pat. No. 4,628,098), OMEPRAZOLE (U.S. Pat. Nos. 4,255,431 and 5,693,818), ESOMEPRAZOLE (U.S. Pat No. 6,369,085) PANTOPRAZOLE (U.S. Pat. No. 4,758,579), and RABEPRAZOLE (U.S. Pat. No. 5,045,552). Some of the diseases treated by proton pump inhibitors and specifically by the five above-

mentioned drugs include peptic ulcer, heartburn, reflux esophagitis, erosive esophagitis, non-ulcer dyspepsia, infection by *Helicobacter pylori*, alrnyitis and asthma.

Whereas the proton pump inhibitor type drugs represent a substantial
5 advance in the field of human and veterinary medicine, they are not totally
without shortcomings or disadvantages. For example, it is believed that the
short systemic half-life of the drug limits the degree of gastric acid suppression
currently achieved. Furthermore, it appears that the short plasma half-life of the
10 drug may contribute to significant gastric pH fluctuations that occur several
times a day in patients undergoing PPI therapy. Additionally, PPIs are acid-
labile, and in most cases it is necessary to enterically coat the drug in order to
prevent the acidic milieu of the stomach from destroying the drug before the
drug is absorbed into systemic circulation. Thus, any contribution that might
15 improve the acid stability or plasma half-life of the presently used proton pump
inhibitors will be a significant improvement in the art.

As further pertinent background to the present invention, applicants note
the concept of prodrugs which is well known in the art. Generally speaking,
prodrugs are derivatives of per se drugs, which after administration undergo
conversion to the physiologically active species. The conversion may be
20 spontaneous, such as hydrolysis in the physiological environment, or may be
enzyme catalyzed. From among the voluminous scientific literature devoted to
prodrugs in general, the foregoing examples are cited: Design of Prodrugs
(Bundgaard H. ed.) 1985 Elsevier Science Publishers B. V. (Biomedical
Division), Chapter 1; Design of Prodrugs: Bioreversible derivatives for various
25 functional groups and chemical entities (Hans Bundgaard); Bundgaard et al. Int.
J. of Pharmaceutics 22 (1984) 45-56 (Elsevier); Bundgaard et al. Int. J. of
Pharmaceutics 29 (1986) 19-28 (Elsevier); Bundgaard et al. J. Med. Chem. 32
(1989) 2503-2507 Chem. Abstracts 93, 137935y (Bundgaard et al.); Chem.
Abstracts 95, 138493f (Bundgaard et al.); Chem. Abstracts 95, 138592n
30 (Bundgaard et al.); Chem. Abstracts 110, 57664p (Alminger et al.); Chem.
Abstracts 115, 64029s (Buur et al.); Chem. Abstracts 115, 189582y (Hansen et

al.); Chem. Abstracts 117, 14347q (Bundgaard et al.); Chem. Abstracts 117, 55790x (Jensen et al.); and Chem. Abstracts 123, 17593b (Thomsen et al.).

A publication by Sih., *et al.* (Journal of Medicinal Chemistry, 1991, vol. 34, pp 1049-1062), describes N-acyloxyalkyl, N-alkoxycarbonyl, N-(aminoethyl), and N-alkoxyalkyl derivatives of benzimidazole sulfoxide as prodrugs of proton-pump inhibitors. According to this article these prodrugs exhibited improved chemical stability in the solid state and in aqueous solutions, but had similar activity or less activity than the corresponding parent compounds having a free imidazole N-H group. This publication provides no data nor suggestion regarding the duration of the inhibitory activity of these prodrugs.

United States Patent No. 6,093,734 and PCT Publication WO 00109498 (published on February 24, 2000) describe prodrugs of proton pump inhibitors which include a substituted arylsulfonyl moiety attached to one of the benzimidazole nitrogens of proton pump inhibitors having the structure identical with or related to proton pump inhibitor drugs known by the names LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE and RABEPRAZOLE.

PCT Publication WO 02/30920 describes benzimidazole compounds which are said to have gastric acid secretion inhibitory and anti *H. pylori* effects. PCT Publication WO 02/00166 describes compounds that are said to be nitric oxide (NO) releasing derivatives of proton pump inhibitors of the benzimidazole structure.

Copending U.S. Patent Application No. 10/620,252, filed July 15, 2003 discloses prodrugs of the proton pump inhibitor type drugs having an arylsulfonyl group with an acidic functional group attached, which provided improved solubility in physiological fluids and improved cell penetration.

BRIEF DESCRIPTION OF THE INVENTION

30

A method comprising orally administering to a mammal a proton pump inhibitor, or a pharmaceutically acceptable prodrug thereof, and a compound

which modulates the activity of MRP2 is disclosed herein, said method being effective for the prevention or treatment of a disease or condition related to gastric acid secretion.

5 A composition comprising a proton pump inhibitor or a prodrug or a pharmaceutically acceptable salt thereof, and a modulator of MRP2 activity is also disclosed herein.

The use of a compound which modulates the activity of MRP2 in the manufacture of a medicament for the prevention or treatment of a condition or disease related to gastric acid secretion afflicting a mammal, said medicament
10 being manufactured for use in conjunction with a proton pump inhibitor or a prodrug or a pharmaceutically acceptable salt thereof, is disclosed herein.

The use of a compound which modulates the activity of MRP2 and a proton pump inhibitor or a prodrug or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of a
15 condition or disease related to gastric acid secretion afflicting a mammal is also disclosed herein.

BRIEF DESCRIPTION OF THE FIGURES

20

Figure 1 is a plot of the systemic half-life ($T_{1/2}$) of proton pump inhibitors omeprazole and lansoprazole, following oral administration of their corresponding prodrugs in dog, as a function of membrane permeability of the prodrugs, measured as the permeability coefficient (P_{app}) across Caco-2 cells in
25 the apical to basolateral direction.

Figure 2 depicts compound 1 transport in the basolateral to apical direction across Caco-2 cells in the presence and absence of 50 μ M of MK-571 and 250 μ M of reduced glutathione.

Figure 3 depicts the mean omeprazole concentration in blood following oral
30 administration of 16 mg/kg compound 6, with and without co-administration of MK-571 (n = 9).


DETAILED DESCRIPTION OF THE INVENTION

While not intending to limit the scope of the invention in any way, or be
5 bound in any way by theory, it is believed that the methods and composition
disclosed herein confer significant advantages to the use and formulation of
proton pump inhibitors and their prodrugs for the treatment and prevention of
diseases and conditions related to gastric acid secretion.


While not intending to limit the scope of the invention in any way, we
10 have surprisingly discovered that a multidrug resistance-associated protein
family member, MRP2, which is expressed at the luminal membrane of the
intestinal epithelium, is likely to be responsible for intestinal efflux of proton
pump inhibitors and their prodrugs, thus prolonging the systemic half life of
these compounds. In other words, it is believed that two-way transport occurs
15 for these compounds, the first transport is absorptive, i.e. from the gut toward
the bloodstream, and the second transport is effluxive, i.e. from the gut lining
back into the lumen of the gastrointestinal tract. Thus, while not intending to be
bound in any way by theory, the effluxive action slows the absorption of the
compounds, and the apparent systemic half-life of the proton pump inhibitors is
20 increased. We have surprisingly discovered that compounds believed to
modulate the activity of MRP2 are capable of altering the net flux of prodrugs
of proton pump inhibitors and proton pump inhibitors from the gut into the
bloodstream and thus altering the pharmacokinetic profile of proton pump
inhibitors. Thus, while not intending to be bound in any way by theory,
25 compounds which modulate the activity of MRP2 are believed to be capable of
helping to tune the pharmacokinetics of prodrugs of proton pump inhibitors and
proton pump inhibitors themselves, thus improving sustained-release,
bioavailability, or peak proton pump inhibitor concentration, according to the
particular need. Furthermore, while not intending to be bound in any way by
30 theory, this discovery should enable separate control of the pharmacokinetic and
physicochemical properties of these compounds, thus improving flexibility in
formulating therapeutic dosage forms.

The term "prodrug" has the meaning previously described herein, and in relation to this disclosure refers to a prodrug of a proton pump inhibitor. The term should be construed broadly, such that if functional groups are present on the prodrug that are capable of forming salts, a salt of such a compound is also considered to be a "prodrug". The term "proton pump inhibitor" also has the meaning previously described herein.

"A compound which modulates the activity of MRP2" is any compound which affects the activity of MRP2, whether it stimulates activity or inhibits activity, regardless of the manner in which this is accomplished. Although the compound may selectively affect the activity of MRP2, nonselective compounds may also be used. Thus compounds which are known to be inhibitors of MRP proteins such as MK-571, sildenafil (Viagra[®]), leukotriene C4, gemfibrozil, probenecid, and verapamil may be used. Compounds such as glutathione, which stimulate MRP activity may also be used. Pharmaceutically acceptable salts of these compounds may also be used, and for the purposes herein, the name of any compound applies to both the neutral form and any pharmaceutically acceptable salt.



MK-571



glutathione

Both proton pump inhibitors and prodrugs may be used in the compositions and methods disclosed herein. While not intending to limit the


scope of the invention in any way, commercially available proton pump inhibitors (PPI) include lansoprazole, esomeprazole, omeprazole, pantoprazole, and rabeprazole. Although a prodrug may be prepared from any proton pump inhibitor, it may be desirable to use a prodrug of a commercially available proton pump inhibitor. In situations where the prodrug is derived from one of the commercially available PPIs circumstances related to the individual to which the prodrug is administered are often relevant to the compositions and methods practiced as disclosed herein. For example, if the person to which the prodrug is being administered is known to respond well to omeprazole, then one may consider using a prodrug of omeprazole as disclosed herein. In another situation, a person may have a history of being effectively treated by lansoprazole, in which case one may consider using a prodrug of lansoprazole as disclosed herein. The specific compounds disclosed herein are given merely to provide guidance and direction to one practicing the invention, and are not intended to limit the overall scope of the invention in any way.

In one embodiment the proton pump inhibitor is lansoprazole. In another embodiment the proton pump inhibitor is omeprazole. In another embodiment the proton pump inhibitor is esomeprazole. In another embodiment the proton pump inhibitor is pantoprazole. In another embodiment the proton pump inhibitor is rabeprazole. Other embodiments comprise a prodrug of omeprazole. Other embodiments comprise a prodrug of pantoprazole. Other embodiments comprise a prodrug of rabeprazole. Other embodiments comprise a prodrug of lansoprazole. Other embodiments comprise a prodrug of esomeprazole.

Certain compounds have been shown to be useful as prodrugs in relation to the embodiments disclosed herein. In certain embodiments, the prodrug comprises a sulfonyl moiety. A "sulfonyl" moiety is defined herein as a moiety comprising an SO_2 group, where a sulfur atom is directly covalently bonded to two oxygen atoms. In other embodiments, the prodrug comprises a phenylsulfonyl moiety. The term "phenylsulfonyl" moiety should be broadly interpreted to mean any moiety where the sulfur of the SO_2 group is directly covalently bonded to a carbon that is part of a phenyl ring. The term "phenyl

ring" should be broadly understood to mean any ring comprising six carbon atoms having three conjugated double bonds. Thus, a phenylsulfonyl moiety could be monosubstituted, meaning that the sulfonyl group is the only group directly attached to the phenyl ring, or the phenylsulfonyl moiety could have
5 from 1 to 5 additional substituents which are not a hydrogen atom, and are directly attached to a carbon of the phenyl ring. In certain embodiments, the prodrug comprises both a phenylsulfonyl moiety and a carboxylic acid or a pharmaceutically acceptable salt thereof.

Prodrugs may also comprise



10

or a pharmaceutically acceptable salt thereof
wherein

A is H, OCH₃, or OCHF₂;

B is CH₃ or OCH₃;

15

D is OCH₃, OCH₂CF₃, or O(CH₂)₃OCH₃;


E is H or CH₃;

R¹, R², R³, and R⁵ are independently H, CH₃, CO₂H, CH₂CO₂H, (CH₂)₂CO₂H, CH(CH₃)₂, OCH₂C(CH₃)₂CO₂H, OCH₂CO₂CH₃, OCH₂CO₂H, OCH₂CO₂NH₂, OCH₂CONH₂(CH₂)₅CO₂CH₃, or OCH₃.

20


In another embodiment related to the one just described, R¹, R², R³, and R⁵ are independently H, CH₃, CO₂H, CH₂CO₂H, (CH₂)₂CO₂H, OCH₂CO₂CH₃, OCH₂CO₂H, OCH₂CONH₂(CH₂)₅CO₂CH₃, or OCH₃.

In certain embodiments, the prodrug has a structure comprising




or a pharmaceutically acceptable salt thereof.

Other prodrugs comprise




5 or a pharmaceutically acceptable salt thereof.

Other prodrugs comprise



or a pharmaceutically acceptable salt thereof.


Other prodrugs comprise




10

or a pharmaceutically acceptable salt thereof.


In other embodiments, the prodrug has a structure comprising



In other embodiments, the prodrug has a structure comprising



In other embodiments, the prodrug has a structure comprising



5

In embodiments comprising a prodrug, the apical to basolateral membrane permeability of the prodrug may vary. The term "apical to basolateral membrane permeability" used in relation to this disclosure refers to the value obtained by carrying out the procedure described in Example 1 herein.

- 10 In one embodiment the apical to basolateral membrane permeability of the prodrug is less than 1×10^{-6} cm/sec. In another embodiment the apical to basolateral membrane permeability of the prodrug is less than 5×10^{-7} cm/sec. In another embodiment the apical to basolateral membrane permeability of the prodrug is less than 1×10^{-7} cm/sec. In another embodiment the apical to
- 15 basolateral membrane permeability of the prodrug is less than 5×10^{-8} cm/sec.

In certain embodiments, the apical to basolateral membrane permeability of a prodrug as it relates to that of the parent proton pump inhibitor is relevant. In one embodiment the apical to basolateral membrane permeability of the

proton pump inhibitor is more than twice the apical to basolateral membrane permeability of the prodrug. In another embodiment, the apical to basolateral membrane permeability of the proton pump inhibitor is more than 10 times the apical to basolateral membrane permeability of the prodrug. In another
5 embodiment the apical to basolateral membrane permeability of the proton pump inhibitor is more than 100 times the apical to basolateral membrane permeability of the prodrug. In another embodiment the apical to basolateral membrane permeability of the proton pump inhibitor is more than 150 times the apical to basolateral membrane permeability of the prodrug.

10 The prodrugs of the present invention can be prepared by the methods described in the following U.S. Patent documents, all of which are expressly incorporated by reference herein: U.S. Pat. No. 6,093,734; U.S. Pat. App. No. 09/783,807, filed February 14, 2001; and U.S. Patent Application No. 10/620,252, filed July 15, 2003; U.S. Pat. App. 10/487,340, filed July 15, 2003.
15 However, these methods are only given to provide guidance, and are not meant to limit the scope of the invention in any way. One of ordinary skill in the art will recognize that there are many ways in which the prodrugs of the present invention can be prepared without departing from the spirit and scope of the present invention.

20 Certain embodiments disclosed herein relate to prodrugs comprising an acidic group. An "acidic functional group" as used herein refers to an oxygen containing functional group which has a pK_a below 10. Thus, while not intending to limit the scope of the claims in any way an acidic functional group may include an organic acid such as a carboxylic acid, a phosphonic acid, or a
25 sulfonic acid.

Acidic functional groups can be in one of two forms, the acid form or the salt form, depending upon whether the particular group has undergone an acid-base reaction. The two forms of these functional groups may also be known by other names. The term "acidic functional group" should be broadly
30 understood to incorporate either the acid or the salt form of the functional group.

A "pharmaceutically acceptable salt" is any salt that retains the activity of the parent compound and does not impart any deleterious or untoward effect on the subject to which it is administered and in the context in which it is administered as compared to the parent compound.

5 Pharmaceutically acceptable salts of acidic functional groups may be derived from organic or inorganic bases. The salt may be a mono or polyvalent ion. Of particular interest are the inorganic ions, lithium, sodium, potassium, calcium, and magnesium. Organic salts may be made with amines, particularly ammonium salts such as mono-, di- and trialkyl amines or ethanol amines. Salts
10 may also be formed with caffeine, tromethamine and similar molecules. Hydrochloric acid or some other pharmaceutically acceptable acid may form a salt with a compound that includes a basic group, such as an amine or a pyridine ring.

A disease or condition related to gastric acid secretion is any disease
15 where gastric acid is a cause or a contributing factor, or contributes to a symptom of the diseases, or where inhibition of gastric acid secretion may be helpful in treating or preventing the disease. While not intending to limit the scope of the invention in any way, some examples of such diseases or conditions are peptic ulcer, heartburn, reflux esophagitis, erosive esophagitis,
20 non-ulcer dyspepsia, infection by *Helicobacter pylori*, alrynitis, and other conditions.

In certain embodiments disclosed herein, the prodrug is not enterically coated. The term "enterically coated" means the prodrug or the dosage form comprising the prodrug is coated by a coating which protects the prodrug from
25 the acids present in the stomach, but which coating disintegrates in the higher pH environment of the intestines. In many dosage forms, small particles of the prodrug are coated with the enteric coating. In other dosage forms, an entire capsule, tablet, or other solid dosage form is coated with the enteric coating. While not intending to be bound in any way by theory, it is believed that the
30 prodrugs disclosed herein are sufficiently stable in the presence of the acidic milieu of the stomach that enteric coating of the prodrug is generally not necessary.


Those skilled in the art will readily understand that for oral administration the compounds of the invention are admixed with pharmaceutically acceptable excipients which per se are well known in the art. Specifically, a drug to be administered systemically, it may be confectioned as a powder, pill, tablet or the like, or as a syrup or elixir suitable for oral administration. Description of the substances normally used to prepare tablets, powders, pills, syrups and elixirs can be found in several books and treatise well known in the art, for example in Remington's Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, Pa.

Prodrugs of the present invention can be combined with certain amounts of the proton pump inhibitors to which they are related to provide a drug-prodrug combination, and the combination administered for inhibition of gastric acid secretion. Thus, certain embodiments relate to a mixture of the prodrug and the proton pump inhibitor. Other embodiments relate to the administration of both the prodrug and the proton pump inhibitor. While not intending to limit the scope of these embodiments, it is believed that the proton pump inhibitor (drug) initially inhibits gastric acid secretion of the patient, and as the effective concentration of the proton pump inhibitor (drug) is decreased by metabolism, the prodrug is used to maintain a sustained presence of a therapeutically effective systemic concentration of the proton pump inhibitor. In certain embodiments the ratio of the molar concentration of the prodrug to the molar concentration of the proton pump inhibitor is from 1 to 1000. In other situations, two prodrugs of a proton pump inhibitor are administered to a person to a similar end.

The following examples provide guidance and direction in making and using the invention, and to demonstrate the advantages of the present invention. However, except in the case of Example 1, they are not to be interpreted as limiting the scope of the invention in any way. In the case of Example 1, it should only be interpreted as limiting in relation to those claims where apical to basolateral membrane permeability is used as a limitation.

Test Compounds

Membrane permeability and oral bioavailability tests were carried out for the compounds shown in Table 1 below. The generic structure, I, is shown as a combination of a proton pump inhibitor (X) and a sulfonyl-bearing moiety which is attached to the proton pump inhibitor to form the prodrug according to the formula below. The identity of each group represented by R¹-R⁵ is shown in the table.



The different possibilities for X are shown below.







Table 1

Compound	X	R ¹	R ²	R ³	R ⁴	R ⁵
1	OME	H	H	OCH ₂ CO ₂ H	H	H
2	OME	CH ₃	H	OCH ₂ CO ₂ H	H	CH ₃
3	OME	H	H	OCH ₂ C(CH ₃) ₂ CO ₂ H	H	H
4	OME	CH ₃	H	OCH ₂ C(CH ₃) ₂ CO ₂ H	H	CH ₃

5	OME	H	H	CH ₂ CO ₂ H	H	H
6	OME	H	CO ₂ H	H	H	H
7	LNZ	H	CO ₂ H	H	H	H
8	LNZ	H	CO ₂ H	OCH ₃	H	H
9	LNZ	H	H	CH ₂ CO ₂ H	H	H
10	LNZ	H	H	OCH ₂ CO ₂ H	H	H
11	LNZ	H	H	OCH ₂ C(CH ₃) ₂ CO ₂ H	H	H
12	LNZ	H	CH ₂ CO ₂ H	CH ₂ CO ₂ H	H	H
13	LNZ	H	CO ₂ H	H	H	CH ₃
14	LNZ	H	CO ₂ H	H	H	OCH ₃
15	LNZ	CH(CH ₃) ₂	H	CH ₂ CO ₂ H	H	H
16	LNZ	H	OCH ₂ CO ₂ H	CO ₂ H	H	H
17	LNZ	CH(CH ₃) ₂	H	OCH ₂ CO ₂ H	H	CH ₃
18	LNZ	H	H	CO ₂ H	H	H
19	LNZ	H	(CH ₂) ₂ CO ₂ H	CH ₃	H	H
20	OME	H	H	OCH ₂ CO ₂ CH ₃	H	H
21	OME	H	H	OCH ₂ CO ₂ NH ₂	H	H
22	OME	H	CO ₂ H	CO ₂ H	H	H
23	OME	H	CO ₂ H	OCH ₂ CO ₂ H	H	H
24	OME	H	OCH ₂ CO ₂ H	OCH ₂ CO ₂ H	H	H
25	OME	OCH ₃	H	CO ₂ H	H	H
26	OME	H		CO ₂ H	H	H
27	OME	H	CO ₂ H	H	H	CH ₃
28	PNT	H	H	OCH ₂ CO ₂ H	H	H
29	PNT	H	CO ₂ H	H	H	CH ₃
30	RAB	H	CO ₂ H	H	H	H
31	RAB	H	CO ₂ H	H	H	CH ₃
32	RAB	CH ₃	H	OCH ₂ CO ₂ H	H	CH ₃
33	RAB	H	H	CO ₂ H	H	H
34	LNZ	CH ₃	H	OCH ₂ CO ₂ H	H	CH ₃
35	LNZ	H	OCH ₂ CO ₂ H	OCH ₂ CO ₂ H	H	H
36	LNZ	H	H	CO ₂ H	H	H
37	LNZ	CH ₃	H	CO ₂ H	H	H
38	LNZ	H	(CH ₂) ₂ CO ₂ H	OCH ₃	H	H
39	OME	CH ₃	H	OCH ₂ CONH ₂ (CH ₂) ₅ CO ₂ CH ₃	H	CH ₃
40	OME	H	H	OCH ₂ CONH ₂ (CH ₂) ₅ CO ₂ CH ₃	H	H
41	OME	H	H	(CH ₂) ₂ CO ₂ H	H	H
42	OME	H	(CH ₂) ₂ CO ₂ H	OCH ₃	H	H

Compounds were prepared according to procedures described the U.S.

Pat. App. No. 10/620,252, filed July 15, 2003 and U.S. Pat. App. No.

5 10/487,340, filed July 15, 2003 incorporated by reference herein.

Omeprazole and lansoprazole were purchased from Sigma (St. Louis, MO).

Example 1

5 Determination of membrane permeability in all examples described herein was accomplished by the following procedure. This procedure is also used to determine whether a given prodrug falls within the scope of those claims given herein which relate to membrane permeability.

10 Materials/Methods

Test System:	Cultured Caco-2 cells and MDR1-MDCK cells
Seeding Density:	2×10^5 cells/cm ² in Costar 12 well Transwell™ plates
15 Culture Age:	17-21 days post seeding for Caco-2 cells, 2-3 days post seeding for MDR1-MDCK cells
Source:	American Type Culture Collection, Manassas, VA (Caco-2) Dr. Piet Borst at the Netherlands Cancer Institute (Amsterdam, Netherlands) (MDR1-MDCK)
20 Growth Media:	Dulbecco's Modified Eagle Media (DMEM) (Gibco BRL) supplemented with 10% fetal bovine serum and 0.1% nonessential amino acids
25 Dosing Formulation:	10 µM proton pump inhibitor or prodrug in DMEM. Make on the day of dosing.
Assay:	LC-MS/MS

Bi-directional transport experiment:

30 Caco-2 and MDR1-MDCK cells were seeded on Costar™ 12mm diameter, 0.4 µm pore size transwell filters, and were cultured at 37°C, 5% CO₂ in a humidified tissue culture chamber.

DMEM was equilibrated as a transport buffer in 37°C water bath an hour before experiment. The cells were then equilibrated in transport buffer for 1 hr at 37°C.

Dosing solution (10 µM) was prepared by adding a 20 µL aliquot of a 10 mM stock solution of the prodrug to 20 mL of transport buffer.

Test Conditions:

Transport across Caco-2 or MDR1-MDCK cell monolayer was measured at 37°C, in the apical to basolateral direction (n=3).

Transport buffer was removed from both apical and basolateral compartment of filters. Dosing solution (0.2 mL) was added to the apical compartment of the cell layers on transwell filters, and 0.8 ml fresh pre-warmed transport buffer was added to basolateral compartment. Timing was started for transport, and at 5, 20, and 60 min after transport started, sample fluid (400 µL) was collected from the basolateral compartment. Fresh transport buffer (400 µL) was added back to the basolateral compartment, and the fluid was thoroughly mixed.

Transport samples, dosing solution, and standards(100 µL) each were mixed with 100 µl of a 500 ng/ml internal standard (Lansoprazole-D) for LC-MS/MS analysis, and part of each sample (100µL) was vortexed and transferred into glass LC-MS/MS vials for analysis.

Data Analysis

The apparent permeability coefficient (P_{app} , cm/sec), otherwise known herein as the membrane permeability, is determined from the following relationship:

$$P_{app} = J/(AC_0)$$

where J (pmol/min) is the transport rate, meaning the rate of prodrug movement through the cell layer, A (cm²) is the filter surface area, and C_0 (µM) is the initial dosing concentration.

The transport rate J, is calculated as the slope of the linear regression fit for the transport amount over time data using Microsoft Excel® 97 SR-2 (Microsoft Corp. Redmond, WA),

5 **Reference Standard:**

Lucifer yellow (LY) was used as a paracellular permeability reference standard to determine integrity of cell layers used in the experiments. LY transport in the apical to basolateral direction was carried out in the same manner as described above. Fluorescence level in basolateral fluid sampled at
10 5, 20, and 60 min post dose was determined using Fluostar Galaxy (BMG Labtechnologies, Durham, NC) at excitation/emission wavelengths of 485/520 nm. A standard curve covering the range from 0.002 to 0.5 mg/mL is constructed to quantify the amount of LY in the transport sample to calculate permeability coefficient (Papp). Papp values below 1×10^{-6} cm/sec were
15 considered acceptable and were used to normalize Papp values for test articles across experiments by multiplying the Papp values for the test articles by the factor x according to the following equation,

$$x = (1 \times 10^{-6})/(S)$$

where S is the value of Papp obtained for LY.

20

Example 2

Oral bioavailability of omeprazole, lansoprazole, pantoprazole, rabeprazole, and test compounds was determined in rats (Sprague-Dawley) and
25 dogs (beagle) by administering an oral solution to the animal and collecting serial blood samples through 24 hr post dose. Blood concentrations of the compounds omeprazole, lansoprazole, pantoprazole, rabeprazole, and test compounds were quantified using an achiral liquid chromatography tandem mass spectrometry method (LC-MS/MS). Systemic pharmacokinetic parameters
30 were determined for omeprazole or lansoprazole using non-compartmental analysis in Watson® version 6.3, available from InnaPhase Corporation,

Philadelphia, PA. Results of the oral pharmacokinetic studies are presented in Tables 2A-2D below.

Table 2A. Systemic Omeprazole Half-life in Rats

Compound Administered	Dosing Route	Equivalent omeprazole dose (mg/kg)	Systemic omeprazole half-life (hr)
Omeprazole	Oral	10	0.31
1	Oral	10	1.7
Omeprazole	Intravenous	1	0.15
1	Intravenous	1	0.18

Table 2A shows the systemic half-life of omeprazole in rats after oral and intravenous administration of omeprazole and compound 1. Surprisingly, these results show that the systemic half-life of omeprazole after intravenous administration of omeprazole is nearly identical to that after intravenous administration of the prodrug (compound 1). The prodrug was not detected in the bloodstream 5 minutes after it was administered intravenously. These unexpected results demonstrate that in the case of compound 1, systemic conversion of the prodrug to omeprazole does not take an appreciable amount of time compared to the amount of time omeprazole is present systemically. By contrast, slowed absorption of the prodrug from the gastrointestinal tract into the blood unexpectedly prolongs the systemic half-life of omeprazole to a significant extent relative to both the intravenous and oral administration of omeprazole. Table 2B shows a similar effect in dogs. Thus, these results show that oral administration of a prodrug will increase the systemic half-life of a proton pump inhibitor. While not intending to limit the scope of the invention, results that will be discussed later, and which are presented in Table 2D, indicate that a relationship may exist between the membrane permeability of the prodrug and the systemic half-life of the proton pump inhibitor.

Table 2B. Systemic Omeprazole Half-life in Dogs

Compound Administered	Dosing Route	Equivalent omeprazole dose (mg/kg)	Systemic omeprazole half-life (hr)
Omeprazole	Oral	10	0.70
1	Oral	10	2.4
Omeprazole	Intravenous	1	0.60
1	Intravenous	1	1.0

Table 2C summarizes the systemic half-lives of the prodrugs and the PPIs for compounds 1-42 in dogs and rats. While not intending to be limited or bound in any way by theory, these results demonstrate that slow absorption of the prodrug from the gastrointestinal tract can contribute to an increase in the systemic half-life of the proton pump inhibitor. For many of the prodrugs in the table, the systemic half-life of the prodrug (i.e. the intact prodrug molecule) is either very short relative to the systemic half-life of the proton pump inhibitor, or is so short that the intact prodrug cannot be detected in the blood, and thus the half-life cannot be detected (NC). By contrast, however, for many of these same prodrugs, the measured systemic half-life of the proton pump inhibitor is significantly increased relative to the orally administered prodrug. Since the hydrolysis of the prodrugs in the blood does not contribute significantly to the increased systemic half-life of the proton pump inhibitors, it follows that the absorption of the prodrug from the gastrointestinal tract is slowed sufficiently to prolong the systemic half-life of the proton pump inhibitor. Thus, while not intending to be bound or limited in any way by theory, in the case of these particular prodrugs, it is the absorption step rather than the hydrolysis step that is the rate-limiting step of the pharmacokinetic process. In other words, the gastrointestinal tract, rather than the bloodstream, acts as the depot for the prodrug.

Table 2C. Systemic Half-Life of Prodrugs and PPIs in Dogs and Rats

Compound	Dog		Rat	
	T _{1/2} Prodrug	T _{1/2} PPI	T _{1/2} Prodrug	T _{1/2} PPI

Omeprazole		0.696 (0.116)		0.308
1	NC	2.08 (1.19)	NC	2.4
2	0.113 (n=1)	1.61		
3	0.311	0.813	NC	1.76(0.93)
4	1.26	0.837	0.342	0.708 (0.479)
5	0.269	1.03	NC	1.7
6	0.303	1.91	NC	1.93 (0.39)
20	NC	2.70 (0.62)		
21	NC	0.855 (0.143)	1.51 (1.44)	0.523 (0.338)
22	NC	3.89		
23	NC	1.22	NC	2.72 (1.35)
24		1.37	NC	0.384
25	NC	1.03		
26	1.19	0.881		
27	0.117 (n=1)	1.10	NC	2.17 (0.53)
39			NC	1.50 (1.18)
40			NC	2.69 (0.76)
41			NC	0.761 (0.497)
42			0.521	1.47 (0.29)
Lansoprazole		0.573 (0.150)		0.510 (0.168)
7	0.206	0.893	NC	1.93 (1.41)
8	NC	1.08	NC	1.80 (1.20)
9	NC	0.894	NC	0.341 (0.151)
10	NC	0.989 (0.307)		
11	NC	0.873 (0.288)	NC	0.933 (1.009)
12	NC	0.931		
13	0.122	1.77	NC	2.35 (1.22)
14	0.118	1.39		0.536 (0.217)
15	NC	0.923		
16	NC	1.00	NC	1.86 (0.74)
17	1.49	1.13		
18	0.0899	0.909		
19	1.84	0.484		
34			NC	1.11 (0.71)
35			NC	1.84 (0.87)
36			NC	0.389 (0.085)
37			NC	2.19 (0.80)
38			1.04 (0.35)	1.43 (0.42)
Pantoprazole		0.743		0.696 (0.116)
28	NC	2.61	NC	1.45 (0.73)
29	NC	0.958	NC	1.01 (0.30)

Rabeprazole		0.369		
30	1.12	0.491		
31	0.843	0.855		
32	0.526	1.52		
33	0.746	0.894		

Values in parenthesis indicate the standard deviation, when obtained.

NC: plasma concentration of prodrug was too low to calculate half-life, or undetected.

5 The results in Table 2D demonstrate that apical to basolateral membrane permeability correlates with the systemic half-life of a PPI after oral administration of a PPI or a prodrug. They also demonstrate that apical to basolateral membrane permeability is a good predictive test for how much a given prodrug will increase the systemic half-life of a PPI because the data shows that decreasing the membrane permeability of a prodrug increases the systemic half-life of the PPI. It should be noted that there is some scatter in the data, which is believed to be due to the relatively large random error in determining the systemic half-life. However, Figure 1 is a plot that graphically demonstrates that despite the scatter, as a general trend, systemic half-life of a PPI resulting from oral administration of its prodrug increases with decreasing membrane permeability of the prodrug.

Table 2D. Membrane permeability of proton pump inhibitors and their prodrugs, and their systemic half-life in dogs after their oral administration.

Compound	Parent PPI	Permeability ($\times 10^{-6}$ cm/sec)	$t_{1/2}$ (hours)
Omeprazole	-	13	0.70
1	Omeprazole	0.12	2.4
2	Omeprazole	0.054	1.6
3	Omeprazole	0.38	0.81
4	Omeprazole	0.52	0.84
5	Omeprazole	0.17	1.0
6	Omeprazole	0.067	1.9
Lansoprazole	-	15	0.57
7	Lansoprazole	0.16	0.89
8	Lansoprazole	0.23	1.1
9	Lansoprazole	0.34	0.89

Example 3

To more completely understand the membrane permeability results presented in the previous examples, transport across Caco-2 or MDR1-MDCK cell layers in both the apical to basolateral (A to B) and basolateral to apical (B to A) directions was measured (n = 3 - 4) for compounds 1 and 6 using the methods described in Example 1. Briefly, dosing solution containing the test compounds at 10 μ M was applied to either the apical or the basolateral side of the cell layer, while the receiver compartment was bathed in DMEM low glucose medium (free of FBS) as the transport buffer. The cells were incubated at either 37°C or 4°C. At 5, 20, and 60 min post dose, aliquots were sampled from the receiver compartment. Each time after sampling, same volume of fresh transport buffer was immediately added back to the receiver compartment and mixed well with the remaining fluid.

P_{app} values in the A to B and B to A directions in Caco-2 and MDR1-MDCK cells for the three different test compounds are listed in Table 3. In Caco-2 cells, all compounds demonstrated preferential transport in the B to A as compared to the A to B direction at 37°C, corresponding to efflux into intestinal lumen in vivo. In other words, while not intending to be bound in any way by theory, these results suggest that following absorption, the cells lining the gastrointestinal tract are able to transport the compounds back into the gastrointestinal tract lumen in the opposite direction of absorption.

When transport was measured for compound 1 in the P-gp over-expressing cell line MDR1-MDCK cells, transport in the efflux direction was not greater. While not intending to be bound in any way by theory, this result suggests P-gp was not involved in the efflux of the prodrugs in Caco-2 cells. Thus, while not intending to be bound in any way by theory, as shown in Example 4, it appears that the activity of MRP2 is responsible for the preferred transport of the compounds in the efflux direction, and consequently, contributes to the reduced absorption rate of the prodrugs and the increased systemic half-life of the PPIs observed when prodrugs are administered orally.

Compound	Caco-2 cells			MDR1-MDCK cells		
	P_{app} AB	P_{app} BA	Ratio	P_{app} AB	P_{app} BA	Ratio

	(cm/sec $\times 10^{-5}$)	(cm/sec $\times 10^{-5}$)	Papp BA / Papp AB	(cm/sec $\times 10^{-5}$)	(cm/sec $\times 10^{-5}$)	Papp BA / Papp AB
OME	1.26	1.63	1.29	2.60	1.71	1.52
1	0.0165	0.0415	2.52	2.39	1.61	0.67
6	0.0172	0.144	8.37	-	-	-

Table 3. Permeability coefficient estimation for omeprazole, compound 1, and compound 6 across Caco-2 and MDR1-MDCK cells.

5

Example 4

Modulating reagents for the multidrug resistant-associated MRP protein were tested in vitro to determine their effect upon transport of compound 1 in Caco-1 cells. In this experiment, dosing solution containing 10 μ M of compound 1 was applied to the basolateral compartment of Caco-2 cell layers (n=4) in the presence and absence of MK-571 (50 μ M) and glutathione (250 μ M) in the apical compartment. MK-571 is a known specific inhibitor for the MRP family [Walgren RA, Karnaky KJ Jr, Lindenmayer GE, and Walle T. Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther 2000; 294:830-6] whereas reduced glutathione (GSH) has been shown to stimulate MRP transport activity [Van Aubel RA, Koenderink JB, Peters JG, Van Os CH, and Russel FG. Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein MRP2 expressed in insect cells. Mol Pharmacol 1999; 56:714-9]. The cells were incubated at 37 °C. At 5, 20, and 60 minutes postdose, samples were taken from the apical chamber.

As shown in Figure 2, in the presence of MK-571 in the apical compartment, transport in the B to A direction was significantly reduced compared to control (Papp = $5.21 \pm 0.50 \times 10^{-6}$ cm/sec versus control Papp = $8.17 \pm 0.38 \times 10^{-6}$ cm/sec, p<0.001). On the other hand, presence of glutathione increased B to A transport by over 60% (Papp = $13.0 \pm 1.7 \times 10^{-6}$ cm/sec, p<0.002). While not intending to be bound in any way by theory, the

inhibition and enhancement of compound 1 B to A transport by MK-571 and GSH respectively suggest that compound 1 is a substrate of MRP2 and is transported by MRP2 in the basolateral to apical direction. While not intending to be limit the invention in any way, or be bound by theory, the in vivo
5 implication of this finding is that MRP2 expressed at the luminal membrane of intestinal epithelial cells may efflux compound 1 in the export direction. Thus, while not intending to be bound by theory, as compound 1 is continuously absorbed and effluxed in the GI tract, its residence time is effectively prolonged and its absorption time window expanded. Further, while not intending to be
10 bound by theory, or limit the scope of the invention in any way, these results suggest that MRP2 modulators may be used to modify the rate the prodrugs are effluxed, thus modifying the absorption time window, as well as the maximum concentration and the plasma half-life of the PPI.

15

Example 5**In Vivo Pharmacokinetic Study on compound 6:**

While not intending to limit the scope of the invention, or be bound in
20 any way by theory, the following in vivo study demonstrates how MRP2 modulators can be used to alter the systemic half life of a PPI after oral administration of a prodrug. Male Sprague-Dawley rats (200-220 g) cannulated in both jugular and femoral veins were purchased from Charles River Laboratories (Wilmington, MA). Two treatment groups with nine animals per
25 group were dosed orally with 16 mg/kg compound 6 in a solution. One group of animals were co-administered an oral dose of 10 mg/kg MK-571 in a solution. Blood samples were collected at 5, 10, 20, 40 minutes, 1, 2, 4, 6 and 8 hours post dosing, mixed with five volumes of acetonitrile, and stored frozen at below -70°C until bioanalysis.

30

Both in vitro transport and in vivo blood samples were analyzed by LC-MS/MS for concentration of omeprazole and the prodrugs, with detection range of 1 – 1000 ng/mL. Deuterated omeprazole served as the internal standard.

Figure 3 shows mean blood omeprazole concentration following dosing. With MK-571 co-administration, maximum blood concentration of omeprazole was significantly increased, as would be expected if efflux of its prodrug is inhibited in the GI lumen by an inhibitor of MRP2. Interestingly, systemic half-life of omeprazole was shortened significantly also. The numeric results of this experiment are compiled in Table 5. Thus while not intending to be bound in any way by theory, this result indicates that the efflux of a prodrug may contribute to the prolonged oral half life of a parent proton pump inhibitor following oral administration of the prodrugs by prolonging the GI residence time of the prodrug. While not intending to be bound in any way by theory, or limit the scope of the invention in any way, this result also demonstrates MRP2 modulators can be used to alter the pharmacokinetic profile of a proton pump inhibitor.

	AUC _{0-∞} (ng•hr/mL)	C _{max} (ng/mL)	t _{1/2} (hr)
Control	56.2 ± 17.0	21.8 ± 12.4	1.64 ± 0.44
+ MK-571	81.0 ± 39.8	43.0 ± 23.9*	1.17 ± 0.41*

Table 5. Estimated pharmacokinetic parameters for omeprazole following oral administration of its prodrug compound 6 with and without co-administration of MK-571 (n = 9). "*" denotes statistically significant difference (p<0.05).

While not intending to limit the scope of the invention in any way, the results presented herein suggest that there are a number of ways that MRP2 modulators could be used to modify the pharmacokinetics to improve the properties, depending upon the circumstances. For example, adding a compound which stimulates MRP2 activity could be used to increase the plasma half life of a proton pump inhibitor by oral administration with a prodrug. Thus, if a particular prodrug has desirable physicochemical properties, but slower absorption is desired, a compound such as glutathione could be administered either separately, or in a single composition with the prodrug. A compound which stimulates MRP2 activity may also be used to improve sustained release of a proton pump inhibitor when it is administered orally, and not as the prodrug. Alternatively, a compound which inhibits MRP2 activity may be used

to provide rapid onset of action and increase the bioavailability of the PPI when used in conjunction with a prodrug that is absorbed more slowly than is desired. This may be useful in providing a faster acting dosage form.

While not intending to limit the scope of the invention in any way, a non-obvious use of a compound such as MK-571, which inhibits MRP2 activity, would be to enhance sustained release of a proton pump inhibitor by oral administration of a prodrug. For example, Figure 3 shows that the concentration of the PPI in the blood is higher from about 0-2 hours when MK-571 is administered with the compound 6 as compared to when compound 6 is administered alone. While not intending to be bound by theory, it is believed that the reduced efflux allows greater systemic absorption of the prodrug, thus producing a higher plasma concentration of the PPI. However, the inhibition of the efflux activity need not occur when the prodrug is administered. For example, in the case of compound 6, if MK-571 is administered about 2 hours after the prodrug is administered, one may expect that the absorption would increase, thus increasing the amount of PPI in the blood for as long as the prodrug is available for absorption. Thus, the total bioavailability of the prodrug might be increased, and the uneven control of stomach pH which is associated with PPI use might be improved. Alternatively, a dosage form might be formulated which allows delayed release of the MRP inhibitor. Thus, both the inhibitors and stimulators of MRP2 activities are useful in improving the pharmacokinetic properties of PPIs and their prodrugs through a large variety of compositions and methods.

Example 6

The physicochemical properties of compound 1 were analyzed. Compound 1 was found to be hygroscopic, in that 9% weight gain was observed for the compound after 14 days of storage at 25 °C at 75% relative humidity.

Table 3A. Solubility Profile of Compound 1 at 25 °C in Buffered Aqueous Solutions

pH	Buffer Composition	Solubility (mg/mL)
----	--------------------	--------------------

1	0.1 M HCl	1.8
3	Citric Acid (0.1 M)/ Na ₂ HPO ₄ (0.2 M)	0.4
5	Citric Acid (0.1 M)/ Na ₂ HPO ₄ (0.2 M)	>50
7	sodium phosphate (0.1 - 0.2 M)	>50
9	sodium phosphate (0.1 - 0.2 M)	>50

The solubility profile of compound 1 in at various pH values is presented in Table 3A. This data shows that the aqueous solubility of the compound is significantly enhanced at around pH 5. While not intending to be bound in any way by theory, it is believed that this improvement in solubility is due to the deprotonation of a sufficient quantity of the acid. While not intending to be bound in any way by theory, this suggests that the prodrug should be significantly easier to formulate, particularly in the case of liquid dosage forms, when the pH is around 5 or higher.

Table 3A. Stability Profile of Compound 1 at 25 °C in Buffered Aqueous Solutions

pH	Buffer Composition	Half-life (t _{1/2}) hours	Shelf life (t _{90%}) hours	Degradation Rate Constant (k) 1/hours
1	0.1 M HCl	3.6	0.5	0.194
3	Citric Acid (0.1 M)/ Na ₂ HPO ₄ (0.2 M)	78.0	11.9	0.009
5	Citric Acid (0.1 M)/ Na ₂ HPO ₄ (0.2 M)	89.2	13.6	0.008
7	sodium phosphate (0.1 - 0.2 M)	286.8	43.6	0.002
7.4	sodium phosphate (0.1 - 0.2 M)	291.2	44.3	0.002
9	sodium phosphate (0.1 - 0.2 M)	23.0	3.5	0.030
10	sodium phosphate (0.1 - 0.2 M)	2.3	0.4	0.298

The aqueous stability data of compound 1 is presented in Table 3B. These results show that, the half-life (t_{1/2}), the shelf-life (t_{90%}), and the rate constant for degradation (k) for compound 1 are significantly improved in the pH range of 3-9. While not intending to be bound in any way by theory, these

results suggest that formulation of dosage forms in the pH range of from 3 to 9 should greatly improve the stability of the prodrugs, thus improving shelf-life and facilitating formulation. Further, these results suggest that dosage forms having a pH from 6 to 8 will be particularly useful in certain situations.

5 Additionally, these results demonstrate that the prodrugs are significantly more stable in acidic and neutral aqueous solutions than the proton pump inhibitors. The stability of omeprazole and other proton pump inhibitors have been reported (Kromer et al., "Differences in pH-Dependent Activation Rates of Substituted Benzimidazoles and Biological in vitro Correlates",
10 Pharmacology 1998; 56:57-70; and Ekpe et al, "Effect of Various Salts on the Stability of Lansoprazole, Omeprazole, and Pantoprazole as Determined by High Performance Liquid Chromatography", Drug Development and Industrial Pharmacy, 25(9), 1057-1065 (1999)), and while the stability is somewhat buffer dependent, typical half-lives for omeprazole are about 1 hour at pH 5 and about
15 40 hours at pH 7, which is about 1-2 orders of magnitude shorter than the prodrug half-lives presented in Table 3A. This instability of the proton pump inhibitors has generally necessitated their formulation in enterically-coated dosage forms. Thus, while not intending to limit the scope of the invention in any way, or to be bound in any way by theory, these results suggest that the
20 prodrugs disclosed herein have sufficient stability to allow the gastrointestinal tract to act as a depot for the prodrug, and also have sufficient stability that the use of enteric coatings is not necessary for effective formulation of a dosage form.

25

Example 7

A capsule containing 40 mg of compound 6 is administered to a patient suffering from heartburn. Two hours later, a capsule containing 40 mg of MK-
571 is administered to the same patient. This therapy is repeated daily, and
30 relief from heartburn is experienced for as long as the therapy continues.

Example 8

Compound 1 (60 mg) and MK-571 (40 mg) are dissolved by stirring into 5 mL of water at 50 °C. The solution is allowed to cool to room temperature, and the entire volume of solution is administered to a patient suffering from heartburn. This procedure is repeated daily, and relief from heartburn is experienced for as long as the therapy continues.


Example 9

A capsule containing compound 6 (60 mg) and glutathione (200 mg) is administered to a patient having an ulcer. This therapy is repeated daily, and relief from symptoms is experienced for as long as the therapy continues.

CLAIMS


What is claimed is:

1. A method comprising orally administering to a mammal
 - a) a proton pump inhibitor, or a pharmaceutically acceptable prodrug thereof, and
 - b) a compound which modulates the activity of MRP2,said method being effective for the prevention or treatment of a disease or condition related to gastric acid secretion.
2. The method of claim 1 comprising a prodrug of a proton pump inhibitor or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 wherein said modulator inhibits MRP2 activity.
4. The method of claim 1 wherein said modulator stimulates MRP2 activity.
5. The method of claim 1 wherein said modulator is MK-571.
6. The method of claim 1 wherein said modulator is glutathione.
7. The method of claim 1 comprising



or a pharmaceutically acceptable salt thereof.


8. The method of claim 1 comprising




or a pharmaceutically acceptable salt thereof.

9. The method of claim 7 comprising MK-571.

10. The method of claim 7 comprising glutathione.
11. The method of claim 8 comprising MK-571.
12. The method of claim 8 comprising glutathione.
13. A composition comprising a proton pump inhibitor or a prodrug or a
5 pharmaceutically acceptable salt thereof, and a modulator of MRP2 activity.
14. The composition of claim 13 comprising a prodrug of a proton pump inhibitor or a pharmaceutically acceptable salt thereof.
15. The composition of claim 13 comprising



- 10 or a pharmaceutically acceptable salt thereof.
16. The composition of claim 13 comprising



or a pharmaceutically acceptable salt thereof.

17. The composition of claim 15 comprising MK-571.
- 15 18. The composition of claim 15 comprising glutathione.
19. The composition of claim 16 comprising MK-571.
20. The composition of claim 16 comprising glutathione.

ABSTRACT

A method comprising orally administering to a mammal a proton pump inhibitor, or a pharmaceutically acceptable prodrug thereof, and a compound
5 which modulates the activity of the MRP2, is disclosed herein, said method being effective for the prevention or treatment of a disease or condition related to gastric acid secretion. This method applied to compounds which both inhibit and stimulate MRP2 activity.

Compositions, medicaments, and experimental results related thereto are
10 also disclosed.

Figure 1




Figure 2





Figure 3



From the INTERNATIONAL BUREAU

PCTNOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

JOHNSON, Brent, A.
c/o Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 28 April 2005 (28.04.2005)	
Applicant's or agent's file reference 17685PCTAP	IMPORTANT NOTIFICATION
International application No. PCT/US05/007015	International filing date (day/month/year) 03 March 2005 (03.03.2005)
International publication date (day/month/year)	Priority date (day/month/year) 11 March 2004 (11.03.2004)
Applicant	ALLERGAN, INC. et al

1. By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).

2. (If applicable) The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

3. (If applicable) An asterisk (*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
11 March 2004 (11.03.2004)	60/552,501	US	07 April 2005 (07.04.2005)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. +41 22 740 14 35

Authorized officer

Biarge-Thurre Marina

Facsimile No. +41 22 338 89 95
Telephone No. +41 22 338 8373